Thymosin Alpha-1
Cellular Longevity and Immune Signalling
£48.00per vial
Thymosin Alpha-1 is a synthetic 28-amino-acid peptide corresponding to an N-terminally acetylated fragment of prothymosin alpha, first characterised in thymic tissue extract. Laboratory work examines it at Toll-like receptors 2 and 9 on antigen-presenting cells, and in thymocyte maturation and cytokine-expression models.
For laboratory research only. Not for human consumption. No medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
This vial is sealed for the protection of health and hygiene. Under regulation 28(1)(e) of the Consumer Contracts (Information, Cancellation and Additional Charges) Regulations 2013, the 14-day right to cancel is lost for this item once that seal is broken. While the seal is intact the right applies in full.
Thymosin Alpha-1 cannot be listed to research users in Australia, Canada, China, India, Italy, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. Verify local eligibility before ordering.
Listed
- Molecular weight
- 3108.3 g/mol
- Sequence
- Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN
- Presentation
- Pre-mixed liquid, 3ml vial
For laboratory research only. Not for human consumption. No medical claims.
- UK DISPATCH
- TRACKED SHIPPING
- COA PER BATCH
- SECURE PAYMENT
§01Compound Profile
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
HPLC
Purity by chromatography
ANALYSED
MASS SPECTROMETRY
Identity confirmation
ANALYSED
PUBLIC COA
Every batch number resolves to its Certificate of Analysis
DOCUMENTED
§02The Science
Published constants and presentation for Thymosin Alpha-1, as catalogued.
Every figure in this list is a published constant or a presentation fact. None of it is an analytical result: the measured figures live on the Certificate of Analysis for the batch.
- Molecular weight
- 3108.3 g/mol
- Sequence
- Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN
- Presentation
- Pre-mixed liquid, 3ml vial
- Batch reference
- TA5615
Molecular weight source: PubChem CID 16130571 (thymalfasin).
§03Certificate of Analysis
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
| PARAMETER | METHOD | RESULT |
|---|---|---|
| Purity | HPLC | 98.5% |
| Identity | Mass spectrometry | Confirmed |
TA5615 · 2026-07-16
§04Compound details
Thymosin Alpha-1, referenced in the literature as thymalfasin, is a 28-residue peptide carrying an acetyl group on its N-terminal serine. It corresponds to a fragment of prothymosin alpha, a nuclear protein from which it is generated by proteolysis, and it was first characterised within thymosin fraction 5, a partially purified bovine thymic extract. The synthetic sequence is used in place of that extract for the reason the extract fell out of use: fraction 5 is a mixture of dozens of peptides, and attributing an observation to any one of them requires the isolated sequence.
The receptor-level work concentrates on the Toll-like receptors. Published studies describe engagement of TLR2 and TLR9 on dendritic cells and monocytes, with signalling through MyD88 to nuclear factor kappa-B and interferon regulatory factor activation, and downstream measurement of interleukin-12, interferon-gamma and tumour necrosis factor transcription. A separate line of investigation examines thymocyte maturation, using the peptide to drive differentiation markers in cultured precursor populations, which is the activity the parent extract was originally characterised for.
The acetylated N-terminus is itself an experimental variable: the unacetylated sequence is reported as substantially less active in the same assays, so the modification is treated as part of the pharmacophore rather than a stability measure. Research contexts include antigen-presentation models, adjuvant characterisation in animal subjects, and studies of immune signalling in immunosuppressed preparations. Thymosin Alpha-1 is catalogued here as a reference compound for laboratory research. No therapeutic, diagnostic, or clinical conclusion is drawn from any study referenced above, and none should be inferred.
Thymosin Alpha-1 is listed as a pre-mixed liquid in a sealed 3ml vial, at 10mg. It is not a lyophilised presentation and there is no reconstitution step for the research user to perform.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography, which resolves the deletion sequences a 28-residue synthesis is prone to. Identity is confirmed by mass spectrometry against the expected mass, which also confirms the N-terminal acetyl group is present, a difference of 42 daltons against the unacetylated sequence. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a batch number that resolves to the public Certificate of Analysis for that batch, reporting the compound, the lot reference, the HPLC result, the mass-spectrometry result, the analysis date, and the laboratory that ran it. The document is published before the batch enters the catalogue.
Research Use Only
Thymosin Alpha-1 is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about Thymosin Alpha-1. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for Thymosin Alpha-1 relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
Thymosin Alpha-1 cannot be listed to research users in the following jurisdictions: Australia, Canada, China, India, Italy, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
Research Context
Thymosin Alpha-1, referenced in the literature as thymalfasin, is a 28-residue peptide carrying an acetyl group on its N-terminal serine. It corresponds to a fragment of prothymosin alpha, a nuclear protein from which it is generated by proteolysis, and it was first characterised within thymosin fraction 5, a partially purified bovine thymic extract. The synthetic sequence is used in place of that extract for the reason the extract fell out of use: fraction 5 is a mixture of dozens of peptides, and attributing an observation to any one of them requires the isolated sequence.
The receptor-level work concentrates on the Toll-like receptors. Published studies describe engagement of TLR2 and TLR9 on dendritic cells and monocytes, with signalling through MyD88 to nuclear factor kappa-B and interferon regulatory factor activation, and downstream measurement of interleukin-12, interferon-gamma and tumour necrosis factor transcription. A separate line of investigation examines thymocyte maturation, using the peptide to drive differentiation markers in cultured precursor populations, which is the activity the parent extract was originally characterised for.
The acetylated N-terminus is itself an experimental variable: the unacetylated sequence is reported as substantially less active in the same assays, so the modification is treated as part of the pharmacophore rather than a stability measure. Research contexts include antigen-presentation models, adjuvant characterisation in animal subjects, and studies of immune signalling in immunosuppressed preparations. Thymosin Alpha-1 is catalogued here as a reference compound for laboratory research. No therapeutic, diagnostic, or clinical conclusion is drawn from any study referenced above, and none should be inferred.
Analysis and Documentation
Thymosin Alpha-1 is listed as a pre-mixed liquid in a sealed 3ml vial, at 10mg. It is not a lyophilised presentation and there is no reconstitution step for the research user to perform.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography, which resolves the deletion sequences a 28-residue synthesis is prone to. Identity is confirmed by mass spectrometry against the expected mass, which also confirms the N-terminal acetyl group is present, a difference of 42 daltons against the unacetylated sequence. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a batch number that resolves to the public Certificate of Analysis for that batch, reporting the compound, the lot reference, the HPLC result, the mass-spectrometry result, the analysis date, and the laboratory that ran it. The document is published before the batch enters the catalogue.
Compliance Notice
Research Use Only
Thymosin Alpha-1 is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about Thymosin Alpha-1. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for Thymosin Alpha-1 relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
Thymosin Alpha-1 cannot be listed to research users in the following jurisdictions: Australia, Canada, China, India, Italy, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
§05Related compounds
§06Questions
No. Thymosin Alpha-1 is catalogued strictly for in-vitro laboratory research. It is not for human or veterinary consumption and no medical claims are made.
Toll-like receptor 2 and 9 engagement on dendritic cells and monocytes, downstream cytokine transcription, and thymocyte maturation in cultured precursor populations. Findings are preclinical.
A synthetic 28-residue peptide corresponding to an N-terminally acetylated fragment of prothymosin alpha. It is referenced in the literature as thymalfasin.
The unacetylated sequence is reported as substantially less active in the same assays, so the modification is treated as part of the pharmacophore rather than as a stability measure. Mass spectrometry confirms it is present on the batch analysed.
Pre-mixed liquid in a sealed 3ml vial, at 10mg. It is not a lyophilised powder and needs no preparation before laboratory use.
Every batch has a document.
The Certificate of Analysis for a batch is published when that batch is released. Your batch number resolves to the report.
For laboratory research only. Not for human consumption. No medical claims.
